Health advocates tout new model of female condom

[A***** A***** 510]

Advocates of the female condom are promoting a less costly, more user-friendly version that they hope will vastly expand its role in the global fight against AIDS and other sexually transmitted diseases.

An early version of the female condom was introduced in 1993, and it remains the only available female-initiated form of protection against both STDs and unintended pregnancy.

Yet despite global promotion by the United Nations and other organizations, its usage is still minuscule, even as women bear an ever-growing share of the AIDS epidemic.

Advocates hope the dynamics will change following last month's approval by the Food and Drug Administration of the FC2, a new version of the female condom produced by the Chicago-based Female Health Co.

About 35 million female condoms were distributed worldwide last year, but that compares with more than 10 billion male condoms, which are far cheaper and, at least initially, easier to use. However, in some nations with high HIV rates, many men refuse to wear condoms, putting women at risk.

Though it looks similar to its predecessor ? a soft, transparent sheath with flexible inner and outer rings ? the FC2 is made from synthetic rubber rather than polyurethane, making it cheaper to produce.

'The mindset is changing, but there are still a lot of challenges.'

? Bidia Deperthes

Mary Ann Leeper, former president of Female Health Co. and now its strategic adviser, said the FC2 also is less noisy during use. Complaints about squeaking were among the factors that slowed acceptance of the original version.

The cost of the FC2 is one-third less than its predecessor, and may go lower, enabling health organizations to distribute many millions more than at present. For now, the price is about 60 cents US compared with less than four cents for mass-distributed male condoms ? a difference that's an issue in the developing world.

'Tremendous victory'

 

The FC2 had been accepted previously by some international organizations, and the Female Health Co. distributed 14 million of them abroad last year along with 21 million of the older version. Advocates of the female condom praised the FDA announcement because it opens the door for the U.S. Agency for International Development (USAID), one of the largest global providers of condoms, to distribute the FC2 overseas.

"This is a tremendous victory," said Susie Hoffman, an assistant professor of clinical epidemiology at Columbia University who contends the female condom has suffered from misconceptions.

"In the United States, there has been strong bias against it," Hoffman said. "Some people involved in AIDS and family planning would say, 'Why do we need these? ? It's so weird that women are not going to pick it up.'"

"But if presented in the right way, many women do like it," Hoffman said. "To find these people and help them and train them, you need systematic programming, which costs money."

Resistance is less of a problem in some developing nations. The UN Population Fund, government agencies and non-profits are aggressively promoting female condoms in places such as Brazil, Ghana, Zimbabwe and South Africa.

Women's groups in Zimbabwe collected more than 30,000 signatures demanding access to the female condom. In Ghana, non-profits say more than 10,000 people have attended training programs that teach women how to insert female condoms ? they require careful instruction to be used properly ? and how to negotiate with their male partners.

"The mindset is changing, but there are still a lot of challenges," said Bidia Deperthes, the Population Fund's HIV technical adviser for condoms. "Accessibility is still minimal. There's a huge demand, and we're not meeting it."

Deperthes hopes that with FDA approval of the FC2, the number of female condoms distributed globally could climb to 50 million this year. If the numbers keep rising, she said, the cost to public-sector distributors for each FC2 could drop as low as 25 cents.

Jeff Spieler, a science adviser with USAID's Office of Population and Reproductive Health, said the female condom's future may depend on whether its promoters can develop a private-sector market. Its commercial price in the United States generally has been more than $2.

Another challenge is a stigma associated with the female condom in some places because prostitutes are among those deemed to benefit most from using it. On the other hand, advocates of the female condom say it has invaluable safe-sex potential for married women whose husbands are unfaithful and shun male condoms.

Serra Sippel, executive director of the Center for Health and Gender Equity in Washington, said FDA approval of the FC2 is a key step toward "putting the power of prevention in women's hands." But she bemoaned the product's limited over-the-counter availability.